Skip to main content

Comorbidities

Comorbidities

16-11-2022 | ACR 2022 | Conference coverage | News

JUVE-BASIS: Support for baricitinib in juvenile arthritis

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

15-09-2022 | Systemic lupus erythematosus | News

Male sex, older age risk factors for acute kidney abnormalities in childhood SLE

Male sex and older age may put people with childhood-onset systemic lupus erythematosus and nephritis at increased risk for abnormal short-term kidney status, US researchers report.

06-09-2022 | Obesity | News

Childhood adiposity link to PsA, SLE risk ‘may not be fully reversible’

Overweight and obesity during childhood may be associated with an increased risk for systemic lupus erythematosus and psoriatic arthritis that persists even if a healthy bodyweight is achieved during adulthood, researchers report.

Close up of a teenage girl wearing a mask being vaccinated

30-08-2022 | COVID-19 | News

Studies bolster evidence for COVID-19 vaccination in young people with RMDs

Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.

01-08-2022 | Lupus nephritis | News

FDA approves belimumab for pediatric lupus nephritis

Click through for more information

24-05-2022 | MIS-C | News

MIS-C clinical features largely unchanged since first COVID-19 wave

The incidence and clinical features of multisystem inflammatory syndrome in children were similar during the delta wave of COVID-19 to those observed during the first year of the pandemic among unvaccinated children and adolescents, Danish research suggests.

16-05-2022 | Juvenile idiopathic arthritis | News

Familial autoimmunity may be linked to celiac disease risk in JIA

Individuals with juvenile idiopathic arthritis have a higher-than-average incidence of celiac disease that may be associated with a family history of autoimmunity and a more severe disease course, Italian researchers report.

Girl wearing mask has plaster applied after receiving vaccine

22-02-2022 | COVID-19 | News

Support for COVID-19 vaccination in adolescents with rheumatic diseases

Study findings suggest that mRNA vaccines against SARS-CoV-2 have good short-term safety and immunogenicity profiles in adolescents with juvenile-onset rheumatic diseases.

09-02-2022 | Juvenile idiopathic arthritis | News

TNF inhibitors linked to psoriasis risk in children with JIA

Exposure to tumor necrosis factor inhibitors is associated with a threefold increased risk for developing psoriasis in children with juvenile idiopathic arthritis, US study findings indicate.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

28-10-2021 | Juvenile idiopathic arthritis | News

Rates of comorbidities in JIA similar across large registries

An analysis of data from three juvenile idiopathic arthritis registries shows “relatively similar” rates of comorbidities among JIA patients, say researchers who believe the finding highlights the potential for the registries to be used for synchronized analyses and harmonized collaborations.

27-09-2021 | COVID-19 | News

​​​​​​​mRNA COVID-19 vaccines well tolerated in young people with JIA

The Pfizer–BioNTech vaccine against SARS-CoV-2 is well tolerated and does not cause disease flares in young people with juvenile idiopathic arthritis treated with TNF inhibitors, suggest findings from a small study.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

27-08-2021 | Juvenile idiopathic arthritis | News

Increased rates of JIA flare during COVID-19 lockdown

Children with juvenile idiopathic arthritis experienced increased rates of flare during the COVID-19 lockdown period, suggest findings from an Italian cohort study.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

13-08-2021 | Rituximab | News

‘Substantial risk’ for hypogammaglobulinemia with rituximab in childhood-onset rheumatic diseases

In a chart review of patients with childhood-onset rheumatic diseases treated with rituximab, over a quarter developed hypogammaglobulinemia and a similar proportion had infectious complications, researchers report.

12-08-2021 | COVID-19 | News

COVID-19 disease course generally mild in children and adolescents with RMDs

In a pediatric cohort of patients with rheumatic and musculoskeletal diseases who contracted SARS-CoV-2, infection was generally mild with good outcomes and had no significant impact on underlying disease activity, report researchers.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

29-06-2021 | MIS-C | News

US survey suggests low rates of multisystem inflammatory syndrome in children with COVID-19

US estimates suggest that 0.03% of SARS-CoV-2 infections lead to multisystem inflammatory syndrome in children, but rates vary by age and race/ethnicity, shows a report published in JAMA Network Open.